Patents Examined by Li Ni Komatsu
  • Chlorotoxin polypeptides and conjugates and uses thereof
    Patent number: 9234015
    Abstract: Reduced lysine chlorotoxin polypeptides that may be used to generate single species conjugates of chlorotoxin. Conjugates comprising such chlorotoxin polypeptides and pharmaceutical compositions thereof. Methods of using such compositions and/or conjugates.
    Type: Grant
    Filed: August 1, 2014
    Date of Patent: January 12, 2016
    Assignee: Morphotek, Inc.
    Inventors: Abdellah Sentissi, Douglas B. Jacoby
  • Process for preparing microparticles
    Patent number: 9226900
    Abstract: A process for preparing microparticles comprising a biologically active material and a polymer and having a mean particle size expressed as the volume mean diameter (VMD) of from 10 to 500 ?m, wherein the biologically active material is substantially insoluble in the polymer, which process comprises: a. contacting a mixture of the biologically active material or a precursor thereof, the polymer or a precursor thereof and a processing aid with a supercritical fluid which is capable of swelling the polymer under temperature and pressure conditions necessary to maintain the fluid in a supercritical state; b. allowing the supercritical fluid to penetrate and liquefy the polymer, while maintaining the temperature and pressure conditions so that the fluid is maintained in a supercritical state; c. releasing the pressure to precipitate microparticles comprising the biologically active agent and the polymer.
    Type: Grant
    Filed: July 10, 2009
    Date of Patent: January 5, 2016
    Assignee: Critical Pharmaceuticals Limited
    Inventors: Andrew Naylor, Andrew Lester Lewis, Lisbeth Illum
  • Peptide for use in the treatment of skin conditions
    Patent number: 9220672
    Abstract: The present invention relates to a peptide of the following formula (I) X1(X2)-X3-X4 or a salt or solvate thereof, wherein is an amino acid comprising two or more NH-functionalities, and X2, X3, and X4 are, independently from one another, an amino acid residue, and wherein the salt or solvate is preferably a physiologically acceptable salt or solvate.
    Type: Grant
    Filed: February 3, 2012
    Date of Patent: December 29, 2015
    Assignee: ORGANOBALANCE GMBH
    Inventor: Christine Lang
  • Antibacterial agents: salinamide derivatives
    Patent number: 9221880
    Abstract: The invention provides compounds of formula (I): and salts thereof, wherein X and Y have any of the values defined herein. The compounds inhibit bacterial RNA polymerase, inhibit bacterial growth, and have applications in, analysis of RNA polymerase structure and function, control of bacterial gene expression, control of bacterial growth, antibacterial chemistry, antibacterial therapy, and drug discovery.
    Type: Grant
    Filed: December 12, 2013
    Date of Patent: December 29, 2015
    Assignee: Rutgers, The State University of New Jersey
    Inventors: Richard H. Ebright, Yon W. Ebright, Yu Feng, David Degen
  • Calcitonin products and therapies for treating inflammatory or degenerative diseases
    Patent number: 9220758
    Abstract: Calcitonin products and therapies for treating inflammatory or degenerative diseases are disclosed herein. The pharmaceutical compositions disclosed herein include a first therapeutic agent that is calcitonin, in free or salt form; a second therapeutic agent selected from the group consisting of a protease inhibitor, an antibiotic, a non-steroidal anti-inflammatory agent, a cyclooxygenase-2 (COX-2) inhibitor and a steroidal anti-inflammatory agent other than glucocorticoid; and a pharmaceutically acceptable excipient, carrier or diluent.
    Type: Grant
    Filed: October 4, 2013
    Date of Patent: December 29, 2015
    Assignee: UGP Therapeutics, Inc.
    Inventors: Nozer M. Mehta, James P. Gilligan
  • Crystalline form of cyclosporine A, methods of preparation, and methods for use thereof
    Patent number: 9206228
    Abstract: The present invention relates generally to crystalline forms of cyclosporine A and particularly to a newly identified form of cyclosporine A. The invention further relates to methods for its preparation and to methods for treating certain ocular disorders.
    Type: Grant
    Filed: July 2, 2014
    Date of Patent: December 8, 2015
    Assignee: Allergan, Inc.
    Inventors: Anuradha V. Gore, Thomas K. Karami, Ke Wu, Richard S. Graham, Scott W. Smith
  • exotoxin A with less immunogenic B cell epitopes
    Patent number: 9206240
    Abstract: The invention provides a Pseudomonas exotoxin A (PE) comprising an amino acid sequence having a substitution of one or more of amino acid residues E420, D463, Y481, L516, R563, D581, D589, and K606, wherein the amino acid residues are defined by reference to SEQ ID NO: 1. The invention further provides related chimeric molecules, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions. Methods of treating or preventing cancer in a mammal, methods of inhibiting the growth of a target cell, methods of producing the PE, and methods of producing the chimeric molecule are further provided by the invention.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: December 8, 2015
    Assignee: The United States of America, as represented by the Secretary, Department of Helath and Human Services
    Inventors: Ira H. Pastan, Masanori Onda, Wenhai Liu
  • Cell growth-promoting peptide and use thereof
    Patent number: 9200257
    Abstract: The pharmaceutical composition provided by the present invention comprises at least one pharmaceutically acceptable carrier, and an active ingredient including an artificially synthesized peptide comprises: (A) an amino acid sequence constituting a cell-penetrating peptide and (B) an amino acid sequence constituting the signal peptide in amyloid precursor protein (APP) or an N-terminal partial amino acid sequence or C-terminal partial amino acid sequence from the amino acid sequence constituting that signal peptide.
    Type: Grant
    Filed: July 25, 2014
    Date of Patent: December 1, 2015
    Assignee: TOAGOSEI CO. LTD.
    Inventors: Tetsuhiko Yoshida, Nahoko Kobayashi
  • Method for reversing recent-onset type 1 diabetes (T1D) by administering substance P (sP)
    Patent number: 9192647
    Abstract: Described herein is a treatment comprising the following step: (a) injecting a therapeutically effective amount of a pharmaceutical composition into the celiac artery of an individual, wherein the pharmaceutical composition reverses recent onset Type 1 Diabetes (T1D). Also described is a method for identifying an individual who will be responsive to this treatment. In addition there is described a device containing the pharmaceutical composition for injecting the pharmaceutical composition into the celiac artery.
    Type: Grant
    Filed: April 4, 2014
    Date of Patent: November 24, 2015
    Inventor: Hans-Michael Dosch
  • Inhibitors of Nox1
    Patent number: 9187528
    Abstract: The present invention relates to inhibitors of Nox1-dependent reactive oxygen species production and their use in the treatment of disorders associated with reactive oxygen species, such as hypertension and cancer.
    Type: Grant
    Filed: May 13, 2014
    Date of Patent: November 17, 2015
    Assignee: UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Daniel J. Ranayhossaini, Patrick Joseph Pagano
  • Anti-microbial peptides and methods of use thereof
    Patent number: 9187541
    Abstract: The present disclosure provides antimicrobial peptides, and compositions comprising same. The present disclosure further provides methods of inhibiting microbial growth.
    Type: Grant
    Filed: April 16, 2012
    Date of Patent: November 17, 2015
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Suzanne M. J. Fleiszig, David J. Evans, Kwai Ping Tam, James J. Mun
  • CAR peptide for homing, diagnosis and targeted therapy for pulmonary and fibrotic disorders
    Patent number: 9180161
    Abstract: Disclosed are compositions and methods useful for delivering targeted therapies for pulmonary diseases, fibrotic disorders and cancer. The compositions and methods are based on peptide sequences that selectively bind to and home to diseased tissue and enable targeted therapies to effect a beneficial therapeutic result. The disclosed targeting is useful for delivering therapeutic and detectable agents to diseased tissue in an animal.
    Type: Grant
    Filed: February 28, 2011
    Date of Patent: November 10, 2015
    Assignees: Sanford Burnham Prebys Medical Discovery Institute, Vascular BioSciences
    Inventors: Masanobu Komatsu, David Marshall Mann, Erkki Ruoslahti
  • Activators of CXCR3 for the treatment of angiopathies of the eye
    Patent number: 9180167
    Abstract: The present disclosure describes methods of treating angiogenic disorders of the eye, such as macular degeneration, restenosis following glaucoma treatment or diabetic retinopathy, by administering an activator of C-X-C chemokine receptor 3(CXCR3). In some embodiments, the activator of CXCR3 is interferon-?-inducible 10 kDa protein (IP-10), or a fragment or variant thereof, such as a fragment comprising or consisting of the C-terminal ?-helix of IP-10. In other embodiments, the activator of CXCR3 is platelet factor 4 (PF4) or a fragment or variant thereof.
    Type: Grant
    Filed: August 23, 2012
    Date of Patent: November 10, 2015
    Assignee: University of Pittsburgh-Of The Commonwealth System of Higher Education
    Inventors: Alan H. Wells, Cecelia C. Yates-Binder, Joel S. Schuman
  • Self-assembling drug amphiphiles and methods for synthesis and use
    Patent number: 9180203
    Abstract: The present invention provides herein the design of monodisperse, amphiphilic anticancer drugs—which are now termed “drug amphiphiles” (DAs)—that can spontaneously associate into discrete, stable supramolecular nanostructures with the potential for self-delivery (no additional carriers are needed). The quantitative drug loading in the resulting nanostructures is ensured by the very nature of the molecular design. The DA is a composition comprising: D-L-PEP; wherein D is 1 to 4 hydrophobic drug molecules which can be the same or different; L is 1 to 4 biodegradable linkers which can be the same or different; and PEP is a peptide that can spontaneously associate into discrete, stable supramolecular nanostructures. In an alternate embodiment, the DA composition also comprises a targeting ligand (T). Methods of making DA molecules, as well as their use in treatment of disease are also provided.
    Type: Grant
    Filed: October 2, 2013
    Date of Patent: November 10, 2015
    Assignee: The Johns Hopkins University
    Inventors: Honggang Cui, Andrew G. Cheetham, Pengcheng Zhang
  • CTRP6 which can be used as therapeutic and prophylactic agent for autoimmune diseases
    Patent number: 9175054
    Abstract: Provided are methods of suppressing complement alternative pathway in a mammalian subject in need thereof, comprising administering to said subject a therapeutically effective amount of C1q and tumor necrosis factor related protein 6 (CTRP6) or a functional analog thereof.
    Type: Grant
    Filed: May 9, 2012
    Date of Patent: November 3, 2015
    Assignee: The University of Tokyo
    Inventors: Yoichiro Iwakura, Masanori Murayama, Harumichi Ishigame, Shigeru Kakuta
  • Compositions and methods for the treatment of cardiac surgery-associated acute kidney injury with annexin A1 peptide
    Patent number: 9173918
    Abstract: The present invention provides a method of treating, ameliorating and/or preventing cardiac surgery-associated acute kidney injury (AKI) in a subject, comprising administering to the subject a therapeutically effective amount of an annexin A1 (ANXA1) peptide such that the AKI is treated, ameliorated and/or prevented.
    Type: Grant
    Filed: October 14, 2011
    Date of Patent: November 3, 2015
    Assignee: Duke University
    Inventors: Zhiquan Zhang, G. Burkhard Mackensen, Qing Ma, Mihai V. Podgoreanu
  • Anti-angiogenic agent and methods of using such agent
    Patent number: 9175063
    Abstract: Anti-angiogenic agents or polypeptides comprising an amino acid segment substantially similar to domain one of CD2 wherein the polypeptide has a ?-sheet formed by two segments. Methods of using such agents and polypeptide are also included.
    Type: Grant
    Filed: July 13, 2011
    Date of Patent: November 3, 2015
    Assignee: Georgia State University Research Foundation
    Inventors: Zhi-Ren Liu, Jenny J. Yang, Yin Lu
  • Mitochondrial penetrating peptides as carriers for antimicrobials
    Patent number: 9173952
    Abstract: There is described herein compounds comprising a mitochondrial penetrating peptide (MPP) conjugated to an antimicrobial, and their method of use.
    Type: Grant
    Filed: May 27, 2011
    Date of Patent: November 3, 2015
    Assignee: The Governing Council of the University of Toronto
    Inventors: Shana Kelley, Mark Pereira
  • Method and pharmaceutical compositions for trans-buccal mucosa treatment of postprandial hyperglycaemia in type II diabetes
    Patent number: 9161910
    Abstract: A method and a pharmaceutical composition in the form of a hydroalcoholic solution in which at least one hypoglycemia-inducing/insulinotropic active principle is dissolved in a stable and complete manner at a dosage that is reduced by 30% to 50% compared with the usual oral unit dosage, for its trans-buccal mucosal application in the spot treatment of postprandial hyperglycemia in type II diabetes in man or animals. Also, disclosed is a method of preparing said formulation and to its specific use in the spot treatment of postprandial hyperglycemia (PPHG) in the context of type II diabetes.
    Type: Grant
    Filed: July 7, 2010
    Date of Patent: October 20, 2015
    Inventors: Philippe Perovitch, Marc Maury, Jean-Pierre Dumonteix
  • Method for the prevention and treatment of sepsis
    Patent number: 9155756
    Abstract: This invention is in the field of medical treatment, in particular the invention provides a method for the prevention and treatment for sepsis or septic shock. The invention provides a novel use of a known medicament, i.e., pentasaccharide-depleted heparin, for use in the treatment or prevention of sepsis, systemic inflammatory response syndrome, severe sepsis or septic shock.
    Type: Grant
    Filed: July 12, 2012
    Date of Patent: October 13, 2015
    Assignees: Universiteit Maastricht, Academisch Ziekenhuis Maastricht
    Inventors: Gerardus Anna Franciscus Nicolaes, Christiaan Peter Maria Reutelingsperger, Hendrik Coenraad Hemker